Intellia Therapeutics (FRA:38I) Cyclically Adjusted Book per Share: €8.27 (As of Mar. 2026)


FRA:38I Intellia Therapeutics Inc FRA:38I
71 GF Score
Price €14.70
GF Value €17.87
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Intellia Therapeutics Cyclically Adjusted Book per Share?

Intellia Therapeutics FRA:38I -0.54% 71 Cyclically Adjusted Book per Share is €8.27 as of Mar. 2026. GuruFocus rates FRA:38I with a GF Score™ of 71/100 and a GF Value™ of €17.87 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Intellia Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was €4.459. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €8.27 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Intellia Therapeutics's average Cyclically Adjusted Book Growth Rate was 5.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-09), Intellia Therapeutics's current stock price is €14.70. Intellia Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €8.27. Intellia Therapeutics's Cyclically Adjusted PB Ratio of today is 1.78.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Intellia Therapeutics was 2.81. The lowest was 0.73. And the median was 1.32.


Intellia Therapeutics  (FRA:38I) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Intellia Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=14.70/8.27
=1.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Intellia Therapeutics was 2.81. The lowest was 0.73. And the median was 1.32.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Intellia Therapeutics Cyclically Adjusted Book per Share Related Terms


Intellia Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Intellia Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intellia Therapeutics Cyclically Adjusted Book per Share Chart

Intellia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 8.57 7.68

Intellia Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.50 8.36 7.96 7.68 8.27

FRA:38I vs MLYS, VCEL, NRIX: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Intellia Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intellia Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Intellia Therapeutics's Cyclically Adjusted PB Ratio falls into.


FRA:38I
71GF Score
Intellia Therapeutics Inc FRA:38I
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intellia Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Intellia Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=4.459/330.2130*330.2130
=4.459

Current CPI (Mar. 2026) = 330.2130.

Intellia Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 5.529 241.018 7.575
201609 5.399 241.428 7.384
201612 5.523 241.432 7.554
201703 5.188 243.801 7.027
201706 4.629 244.955 6.240
201709 4.089 246.819 5.471
201712 5.993 246.524 8.027
201803 5.561 249.554 7.358
201806 5.537 251.989 7.256
201809 5.202 252.439 6.805
201812 5.608 251.233 7.371
201903 5.144 254.202 6.682
201906 5.135 256.143 6.620
201909 5.121 256.759 6.586
201912 4.839 256.974 6.218
202003 4.431 258.115 5.669
202006 5.317 257.797 6.811
202009 4.760 260.280 6.039
202012 6.541 260.474 8.292
202103 6.754 264.877 8.420
202106 6.010 271.696 7.304
202109 12.658 274.310 15.238
202112 12.360 278.802 14.639
202203 11.452 287.504 13.153
202206 10.960 296.311 12.214
202209 10.879 296.808 12.103
202212 13.391 296.797 14.899
202303 12.625 301.836 13.812
202306 11.543 305.109 12.493
202309 10.910 307.789 11.705
202312 10.355 306.746 11.147
202403 9.895 312.332 10.461
202406 9.178 314.175 9.647
202409 8.520 315.301 8.923
202412 8.162 315.605 8.540
202503 6.968 319.799 7.195
202506 5.887 322.561 6.027
202509 5.507 324.800 5.599
202512 4.929 324.054 5.023
202603 4.459 330.213 4.459

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €8.27 mean?
Intellia Therapeutics (FRA:38I) has a Cyclically Adjusted Book per Share of €8.27 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Intellia Therapeutics and its competitors.
Is Intellia Therapeutics' Cyclically Adjusted Book per Share too high?
Intellia Therapeutics' current Cyclically Adjusted Book per Share is €8.27. Overall, Intellia Therapeutics has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Intellia Therapeutics' Cyclically Adjusted Book per Share compare to MLYS and VCEL?
Intellia Therapeutics' Cyclically Adjusted Book per Share of €8.27 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Intellia Therapeutics and its competitors. Intellia Therapeutics's current Cyclically Adjusted Book per Share is €8.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intellia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Intellia Therapeutics (FRA:38I) is currently considered Modestly Undervalued. The stock's GF Value™ is €17.87, compared to a current price of €14.70 — trading 17.7% below its estimated fair value. The current Cyclically Adjusted Book per Share is €8.27. Intellia Therapeutics' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Intellia Therapeutics (FRA:38I), the current Cyclically Adjusted Book per Share is €8.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intellia Therapeutics (FRA:38I) Overvalued in 2026?

Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be undervalued. The current stock price of €14.70 is trading 17.7% below its estimated GF Value™ of €17.87. GuruFocus considers Intellia Therapeutics to be Modestly Undervalued.

Key valuation signals for FRA:38I:

  • Cyclically Adjusted Book per Share: €8.27
  • GF Value™: €17.87 vs. price of €14.70 (17.7% below fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the FRA:38I stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Intellia Therapeutics Business Description

Other Exchanges NTLA:USA0JBU:UK38I:Germany
Address 40 Erie Street, Suite 130, Cambridge, MA, USA, 02139
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
71GF Score

Get the complete analysis for FRA:38I

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.70
Price
€17.87
GF Value